Biblio
Export 1482 results:
Author Title Type [ Year![(Desc)](https://www.j-alz.com/sites/all/modules/contrib/biblio/misc/arrow-desc.png)
Filters: First Letter Of Last Name is H [Clear All Filters]
“Noninvasive Gamma Sensory Stimulation May Reduce White Matter and Myelin Loss in Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 359-372, 2023.
, “A Novel Strategy for Alzheimer's Disease Based on the Regulatory Effect of Amyloid-β on Gut Flora.”, J Alzheimers Dis, vol. 94, no. s1, pp. S227-S239, 2023.
, “Patterns of Aging Changes in Bodyweight May Predict Alzheimer's Disease.”, J Alzheimers Dis, vol. 97, no. 1, pp. 163-170, 2023.
, “Plasma ApoE4 Levels Are Lower than ApoE2 and ApoE3 Levels, and Not Associated with Plasma Aβ 40/42 Ratio as a Biomarker of Amyloid-β Amyloidosis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 93, no. 1, pp. 333-348, 2023.
, “Poor Oral Health as a Risk Factor for Dementia in a Swedish Population: A Cohort Study with 40 Years of Follow-Up.”, J Alzheimers Dis, vol. 92, no. 1, pp. 171-181, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications.”, J Alzheimers Dis, vol. 96, no. 2, pp. 429-437, 2023.
, “Proteome Network Analysis Identifies Potential Biomarkers for Brain Aging.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1767-1780, 2023.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Psychopharmacological Medication Use in Frontotemporal Dementia at the Time of Diagnosis: Comparison with Alzheimer's Disease.”, J Alzheimers Dis, vol. 95, no. 2, pp. 677-685, 2023.
, “Racial/Ethnic Disparities in Misidentification of Dementia in Medicare Claims: Results from the Washington Heights-Inwood Columbia Aging Project.”, J Alzheimers Dis, vol. 96, no. 1, pp. 359-368, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers.”, J Alzheimers Dis, vol. 94, no. 2, pp. 483-489, 2023.
, “A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes.”, J Alzheimers Dis, vol. 96, no. 2, pp. 591-607, 2023.
, “A Remotely Coached Multimodal Lifestyle Intervention for Alzheimer's Disease Ameliorates Functional and Cognitive Outcomes.”, J Alzheimers Dis, vol. 96, no. 2, pp. 591-607, 2023.
, “Retinal Functional and Structural Neural Indices: Potential Biomarkers for the Monitoring of Cerebral Neurodegeneration: The Maastricht Study.”, J Alzheimers Dis, vol. 93, no. 4, pp. 1471-1483, 2023.
, “The Role of Interferon-α in Neurodegenerative Diseases: A Systematic Review.”, J Alzheimers Dis, vol. 94, no. s1, pp. S45-S66, 2023.
, “S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1489-1504, 2023.
, “S1PR2 Regulates Autophagy Through the AKT/mTOR Pathway to Promote Pathological Damage in Alzheimer's Disease.”, J Alzheimers Dis, vol. 96, no. 4, pp. 1489-1504, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Safety, Feasibility, and Potential Clinical Efficacy of 40 Hz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study.”, J Alzheimers Dis, vol. 92, no. 2, pp. 653-665, 2023.
, “Serotonin Degeneration and Amyloid-β Deposition in Mild Cognitive Impairment: Relationship to Cognitive Deficits.”, J Alzheimers Dis, vol. 96, no. 1, pp. 215-227, 2023.
, “Soluble TREM2, Alzheimer's Disease Pathology, and Risk for Progression of Cerebral Small Vessel Disease: A Longitudinal Study.”, J Alzheimers Dis, vol. 92, no. 1, pp. 311-322, 2023.
,